Last reviewed · How we verify
NCT02697578
Artificial Intelligence: a New Alternative to Analyse CKD-MBD in Hemodialysis
trial in Chronic Kidney Disease Mineral and Bone Disorder in 197 participants. Completed in 19 December 2018.
19 December 2018
Quick facts
| Lead sponsor | Maimónides Biomedical Research Institute of Córdoba |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 197 |
| Start date | 1 February 2016 |
| Primary completion | 19 December 2018 |
| Estimated completion | 19 December 2018 |
| Sites | 1 location across Spain |
Conditions studied
- Chronic Kidney Disease Mineral and Bone Disorder — all drugs for Chronic Kidney Disease Mineral and Bone Disorder →
Sponsor
Maimónides Biomedical Research Institute of Córdoba
Who can join
Adults 18 to 90, any sex, with Chronic Kidney Disease Mineral and Bone Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The regulation of calcium, phosphate and parathyroid hormone in hemodialysis is complex and each parameter is not independently regulated. Simultaneous modification in these three parameters are the result of abnormal mineral metabolism and the treatment used. The specific objective of this work is an accurate and exhaustive analysis and description of the complex relationships between clinically relevant parameters in chronic kidney disease metabolism bone disease. In order to achieve these objectives we have used a machine learning approach Random Forest able to extract useful knowledge from a large database. The analysis of the complex interactions between the different parameters needs an advance mathematical approach such as Random Forest . The second aim of this study is to determine whether calcium, phosphate and parathyroid hormone, Fibroblast growth factor 23 and calcitriol are long-term associated with demographic features, mortality, co-morbidity and the therapy prescribed. We will analyze in a prospective study on incident patients, whether the use of this new model may predict the cardiovascular risk..
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Phosphate control in reducing FGF23 levels in hemodialysis patients.
Rodelo-Haad C, Rodríguez-Ortiz ME, Martin-Malo A, Pendon-Ruiz de Mier MV, et al · · 2018 · cited 26× · PMID 30086150 · DOI 10.1371/journal.pone.0201537
Verify or expand the search:
- PubMed search for NCT02697578
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Kidney Disease Mineral and Bone Disorder
Currently open trials in the same condition.
- NCT07171216 — The Effect of REgulation of PArathyroId hoRmone in Patients With Chronic Kidney Disease to Investigate the Change in Bon · NA · recruiting
- NCT07368946 — Phosphate Assessment in Chronic Kidney Disease Patients Study · NA · recruiting
Other Maimónides Biomedical Research Institute of Córdoba trials
Trials by the same sponsor.
- NCT06783491 — Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Ad · Phase 3 · not yet recruiting
- NCT07479303 — Vitamin D Status in Young Medical Residents · completed
- NCT07178379 — Hysteroscopy Anesthesia for Relief of Pain · NA · not yet recruiting
- NCT06712485 — Biomarkers in EV Associated With Marrow Adiposity in Anorexia · not yet recruiting
- NCT06579846 — 12-Month Efficacy of Exercise and Cytisinicline for Tobacco Abstinence · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02697578 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Maimónides Biomedical Research Institute of Córdoba
- Last refreshed: 21 December 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02697578.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing